MMV develops framework to assess risk of resistance for antimalarial compounds

August 22, 2012

Medicines for Malaria Venture has developed a framework to evaluate the risk of resistance for the antimalarial compounds in its portfolio. A paper based on this work: A framework for assessing the risk of resistance for antimalarials in development has been published in the Malaria Journal today.

Resistance defines the longevity of every anti-infective drug, so it is important when developing for malaria, to check how easily promising antimalarial compounds will select for resistance. Once this is known, it facilitates the prioritization of not only the most efficacious compounds but also the most robust ones.

"By profiling our portfolio as early as possible in terms of resistance liabilities, be they pre-existing or acquired, we are attempting to ensure that none of the compounds will fall to potential resistance," said Tim Wells, Chief Scientific Officer, MMV, and one of the authors of the paper. "This will also help us cost-effectively accelerate the drug development process, and be prepared in advance with a full resistance profile which is required by regulatory authorities before a new drug can be approved."

A cross- using a panel of multi-drug of the parasite will check for pre-existing resistance liability. This will ensure that none of MMV's compounds are cross-resistant with other drugs, e.g., if a parasite is resistant to , its resistance will also be profiled against MMV compounds.

The framework also includes selection experiments in the laboratory that measure how easy it is for the parasite to develop resistance, in other words, the likelihood of the occurrence of mutations that confer resistance. This is achieved by measuring the minimal inoculum for resistance (MIR) – the minimum number of parasites from which a resistant one is likely to be selected by drug pressure. Although this is already being done, the framework offers a standard, systematic method.

This new framework will result in a fully profiled portfolio for MMV in terms of resistance and could also be used by other malaria researchers to test their compounds for potential resistance, measure the genetic ability of to develop resistance and the intensity of the resistance.

Explore further: Screening effort turns up multiple potential anti-malaria compounds

Related Stories

Recommended for you

Listeria infection causes early pregnancy loss in primates

February 21, 2017

Researchers in Wisconsin have discovered how Listeria monocytogenes, a common foodborne pathogen, travels through the mother's body to fatally attack the placenta and fetus during early pregnancy in a macaque monkey.

Listeria may be serious miscarriage threat early in pregnancy

February 21, 2017

Listeria, a common food-borne bacterium, may pose a greater risk of miscarriage in the early stages of pregnancy than appreciated, according to researchers at the University of Wisconsin-Madison School of Veterinary Medicine ...

Ebola linked to habitat destruction

February 20, 2017

A Massey University veterinary scientist has co-authored research suggesting that Ebola virus emergence is linked to the clearing of animal habitat through deforestation in West and Central Africa.

Researcher helps stem the spread of superbugs

February 20, 2017

Katherine Baker feels vindicated. She and other microbiologists have been warning for years that anti-bacterial soaps containing triclosan are bad for the environment, harmful for health, and do nothing to prevent disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.